Ferrer, a prominent international pharmaceutical company based in Barcelona, Spain, has announced the successful completion of patient recruitment for the PROSPER study, a Phase II clinical trial aimed at evaluating the efficacy and safety of FNP-223 in treating Progressive Supranuclear Palsy (PSP). This milestone was achieved two months ahead of the planned schedule, with a total of 220 participants enrolled within just 14 months. The trial, which is randomized, double-blind, and placebo-controlled, is being conducted across 44 clinical centers located in the European Union, the United Kingdom, and the United States.
The PROSPER study is specifically designed to assess the potential of FNP-223, an oral formulation that acts as a selective inhibitor of the O-GlcNAcase enzyme, in slowing the progression of PSP, a rare and rapidly advancing neurodegenerative disorder. Currently, there are no approved therapies that modify the course of PSP, making this research particularly significant. The trial will involve a six-week screening period followed by 52 weeks of treatment, with participants receiving either FNP-223 or a placebo, and concluding with a four-week follow-up phase.
Progressive Supranuclear Palsy is characterized by severe neurological decline, typically affecting individuals over the age of 60. The disease is caused by the abnormal accumulation of tau protein in critical brain regions, leading to debilitating symptoms such as loss of balance, cognitive disturbances, and difficulties with speech and swallowing. Given the complexity of diagnosing PSP at its early stages, which is crucial for effective intervention, the expedited recruitment of participants underscores the collaborative effort of researchers and healthcare professionals involved in the study.
Prof. Dr. Med. Günter Höglinger, principal investigator and coordinator of the PROSPER study from Ludwig-Maximilian University of Munich, expressed his gratitude towards the patients, caregivers, and research teams for their commitment, which played a pivotal role in achieving this significant milestone swiftly. He noted that the study aims to explore the impact of OGA inhibition on PSP, a critical area of scientific inquiry that could lead to transformative solutions for those affected by the disease.
The significance of achieving full enrollment in this clinical trial was also highlighted by Kristophe Diaz, CEO of CurePSP. He remarked that the recruitment success reflects both scientific progress and a commitment to the PSP community, noting that the participation of patients and their families is essential for advancing meaningful therapies.
In addition to its clinical objectives, Ferrer has committed to incorporating insights from patients and healthcare providers into the study’s design, ensuring that the research aligns with the real needs of those affected by PSP. This approach aims to enhance the participant experience and improve the overall impact of clinical research.
Founded in 1959, Ferrer focuses on developing innovative treatments for conditions with high unmet medical needs, particularly in the realms of rare neurological diseases and pulmonary conditions. With ongoing studies like PROSPER, the company continues to reinforce its mission to create a positive social impact through the development of transformative healthcare solutions for serious diseases.
Related
